$OSCR

Schlosser Mario sold $22.8M of OSCR

Schlosser Mario sold 750,000 shares of Oscar Health, Inc. (OSCR) at an average of $30.43 ($30.34–$30.79, $22.82M total) across 2 trades over 2026-08-27 to 2026-08-28.

Original reporting
SEC EDGAR · Schlosser Mario
Published Aug 31, 2026, 8:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 31, 2026, 9:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OSCR
Bearish
medium confidence
Mentioned
$OSCR
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OSCRBearishLow
01

Why it matters

The director's sale may be interpreted as a negative signal, but could also be a personal liquidity decision.

02

Market read

Primary insider sale; traders may adjust short positions or monitor price action.

03

What to watch

Potential upcoming capital raise or strategic transaction that requires cash.

Relevance 7/10Novelty 7/10Timing: after market close on 2026-08-31

Background

Form 4 filing provides the first public disclosure of the insider transaction.

Company-level read

Ticker impact

$OSCRBearishMedium confidence
Context

Director Mario Schlosser sold 750,000 shares for $22.8M, reducing his stake to 480,866 shares.

Expected impact

Potential short‑term downward pressure on OSCR price.

Evidence & confidence

The $22.8M sale represents a material reduction of insider ownership and is disclosed via a Form 4, which traders often view as a bearish signal.

Market effects

May raise concerns for the health‑tech sector if other insiders follow suit.

Limited to US markets where OSCR trades.

Minimal global impact beyond Oscar Health investors.

Counterpoint

The sale could be a routine liquidity event unrelated to company fundamentals.

Key entities

  • Oscar Health, Inc.

    US‑listed health‑tech insurer (NASDAQ: OSCR).

  • Mario Schlosser

    Director of Oscar Health who executed the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$OSCRHighAI 8/10

OSCR Looks 33.9% Overvalued on GF Value™ as Oscar Health Revises

Oscar Health (OSCR) revised its 2026 forecasts, raising operating earnings outlook by $100M to $600M-$800M and improving medical loss ratio guidance. Revenue guidance remains $18.7B-$19B. GF Value™ indicates OSCR is 33.9% overvalued at $32.44. The company has a strong GF Score™ of 83/100, with high growth and momentum ratings but middling profitability and valuation. Insiders have sold significantly more shares than they've bought.

$OSCRHighAI 8/10

Oscar Health boosts 2026 earnings outlook, affirms revenue

Oscar Health (OSCR) updated its 2026 earnings outlook, lowering its Medical Loss Ratio to 81.0%-82.0% and raising earnings from operations to $600M-$800M. The company reaffirmed revenue guidance of $18.7B-$19.0B and maintained SG&A expense ratio targets. The updates will be discussed at its 2026 Investor Day on September 16, 2026.

$OSCRHighAI 8/10

Oscar Health raises FY26 earnings guidance by $100 million

Oscar Health (OSCR) raised its 2026 earnings guidance by $100 million, citing improved cost controls. The company expects earnings from operations to range from $600 million to $800 million, with a medical loss ratio of 81.0% to 82.0%. Total revenue guidance remains unchanged at $18.7 billion to $19.0 billion. The stock has gained 85.57% over the past year, reaching a 52-week high of $27.59.

$CNCMed

CNC, OSCR Stocks Rally After Baird Calls Risk Adjustment Results Favorable

Centene (CNC) and Oscar Health (OSCR) shares rose 6% and 12% respectively after Baird reported favorable risk adjustment results. Baird noted the outcomes support Centene's Q4 commentary and align with Oscar's June investor conference remarks. Molina (MOH) shares also rose 2% despite a minor negative impact. The Centers for Medicare & Medicaid Services released final 2025 risk adjustment data on June 30, affecting insurers' earnings.